Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
About
About
EQOH
Careers
HCP Jobs
Contact Us
EMJ Gold
search
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
About
About
EQOH
Careers
HCP Jobs
Contact Us
EMJ Gold
Subscribe
FREE
Subscribe to EMJ GOLD
Subscribe to EMJ
Edition
European
US
Oncology
Filter
Journals
About
Congress reviews
Abstracts
Articles
Podcasts
Videos & Webinars
News
Infographics
Submit A Paper
Integration of Immuno-Oncology into Contemporary Management of Muscle-invasive Urothelial Carcinoma
June 2024
At the European Association of Urology (EAU) 2024 Conference, Jürgen Gschwend (Department of Urology, Hopital Rechts der Isar Technical…
Read more
26th June 2015
Results of the phase 3 ELOQUENT-2 trial
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta, GA…
26th June 2015
Results of the phase 3 PERSIST-1 trial of pacritinib for myelofibrosis
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jean-Jacques Kiladjian, MD, PhD, of Saint-Louis Hospital & Université Paris…
26th June 2015
Results of the phase 2 54767414MMY2002 (Sirius) trial of daratumumab for multiple myeloma
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ, discusses the results of…
26th June 2015
DNMT3A R882 mutations in AML promote chemoresistance and therapeutic relapse
Multivariate analysis of patients with acute myeloid leukaemia (AML) at day 28 in clinical or pathologic complete remission showed that DNMT3A R882…
26th June 2015
Updated results from the SORAML trial of sorafenib in younger patients with newly diagnosed AML
The randomised, controlled phase 2 SORAML trial showed that the addition of the tyrosine kinase inhibitor, sorafenib, to chemotherapy improved event-free…
26th June 2015
Phase 3 CheckMate 067 trial of nivolumab in previously untreated advanced melanoma
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, James Larkin, FRCP, PhD, Consultant Medical Oncologist at The Royal Marsden…
26th June 2015
Whole Brain Radiation Therapy is More Harmful Than Beneficial for Small Brain Metastases
In the phase 3 NCCTG N0574 (Alliance) trial, patients with 1 to 3 small brain metastases were randomised to receive stereotactic radiosurgery (SRS) alone…
26th June 2015
Elective Neck Dissection Improved Survival in Early Node-Negative Oral Cancer
A phase 3, randomised controlled trial showed that elective neck dissection improved overall survival by 12.5% and reduced risk of death by 36% when…
Loading posts...
« Previous
1
…
38
39
40
41
42
…
46
Next »